D. Boral Capital Reaffirms Buy Rating for Immunic (NASDAQ:IMUX)
Immunic (NASDAQ:IMUX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $17.00 price objective on the stock. Several other research firms also recently commented on IMUX. StockNews.com downgraded Immunic from a “hold” rating to […]
Immunic (NASDAQ:IMUX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $17.00 price objective on the stock. Several other research firms also recently commented on IMUX. StockNews.com downgraded Immunic from a “hold” rating to […]
